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The Skin-Associated Lymphoid 
Tissue-Related B-Cell Lymphomas 
Nicola Pimpinelli and Marco Santucci 
Primary cutaneous B-cell lymphomas (CBCLs) 
should be clearly separated from non-Hodgkin's 
B-cell lymphomas with secondary cutaneous in- 
volvement and from cutaneous B-cell pseudolym- 
phomas. The majority of CBCLs are characterized 
by a homogeneous clinical presentation and be- 
havior, with good response to local radiotherapy, 
low tendency to extracutaneous spread, and ex- 
cellent prognosis. According to the European Orga- 
nization for Research on the Treatment of Cancer 
classification of primary cutaneous lymphomas, 
CBCLs with an indolent behavior are divided into 2 
subgroups: follicular center cell lymphoma and 
immunocytomalmarginal zone lymphoma, due to 
putative histologic similarities with their purported 
nodal counterparts. In addition, a third subgroup 
with intermediate prognosis (large B-cell lym- 
phoma of the leg) is identified. Conversely, the 
identification of distinct subgroups is disputable 
from a strictly histologic, immunophenotypic, and 
genotypic point of view, and has neither correla- 
tion with the clinical course nor the prognosis of 
the disease. Moreover, the majority of CBCLs show 
a uniform immunophenotype (CDS-,  CD10- )  and 
genotype (lack of bcl-11bcl-2 and c-myc gene 
rearrangement) of neoplastic cells. Therefore, we 
favor the use of the term Skin-Associated Lym- 
phoid Tissue (SALT)-related B-cell lymphomas, due 
to the close similarities between CBCLs and mu- 
cosa-associated lymphoid tissue (MALT) lympho- 
mas, and the evidence for an acquired B-cell arm 
of SALT. 
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A LTHOUGH PRIMARY cutaneous B-cell lympho- mas (CBCLs) have been recognized since 1978, L2 
studies on patients published before 1987 did not 
distinguish between primary and secondary/concur- 
rent cutaneous presentations. 3-T This is based on the 
common opinion that cutaneous lymphomas, other 
than mycosis fungoides, represented issemination 
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from nodal disease. Conversely, B-cell cutaneous disor- 
ders characterized clinically by indolent behavior, good 
response to local treatment, and favorable prognosis 
and histologically by "top heavy" distribution of the 
infiltrate, cytologic polymorphism (small and large 
cells), and the presence of lymphoid follicles were 
invariably regarded as reactive processes (B-cell pseudo- 
lymphomas [B-PLs]). 2,8"n 
Studies of large groups of patients---carefully se- 
lected on the basis of primary cutaneous presentation, 
no evidence of extracutaneous di ease, and monoclonal- 
ity of neoplastic B cellsl2q~--demonstrated that CBCLs 
are indeed a distinct group of lymphoproliferative 
diseases that should be distinguished from non- 
Hodgkin's B-cell lymphomas with secondary cutaneous 
involvement and from cutaneous B-PLs. 
The majority of CBCLs are characterized bya homo- 
geneous clinical presentation and behavior, ~vith good 
response to nonaggressive treatments (mostly local 
radiotherapy), a low tendency of extracutaneous spread, 
and excellent prognosis, o that they have been defined 
as semimalignant ("pseudolymphomatous"). 16 On the 
basis of the "classic" interpretation proposed by the 
Dutch Cutaneous Lymphoma Working Group 
(DCD, VG), 17 this large group of CBCLs are currently 
classified as follicle center cell lymphoma (FCCL) ~2,1s 
and immunocytoma (IC) 19 or marginal zone lym- 
phoma (MZL), 2~ according to the recently published 
European Organization for Research and Treatment of 
Cancer (EORTC) classification of primary cutaneous 
lymphomas. 22
Indeed, on the basis of the close similarities with 
mucosa-associated lymphoid tissue (MALT) lympho- 
mas 23 and the evidence for an acquired B-cell arm of the 
skin-associated lymphoid tissue (SALT), we proposed 
the designation of these CBCLs as SALT-related B-cell 
lymphomas. 24This term, which encompasses the "tra- 
ditional" histologic categories (FCCL and IOMZL), 
should be regarded both as a concept and as a diagnos- 
tic category. This article ~vill show the clinical, histo- 
logic, immunophenotypic, and molecular bases of our 
interpretation. 
The clinicopathologic significance of a smaller group 
of CBCLs (so-called primary cutaneous large B-cell 
lymphoma of the leg), 25 characterized by: (1) rapid 
growth of skin lesions; (2) large cell histology, high 
proliferation rate, and bcl-2 protein expression by 
neoplastic ells at presentation; and (3) possible predi- 
124 Seminars in Cutaneous Medicine and Surgery, Vo119. No 2 (June), 2000: pp 124-129 
SALT-RELATED B-CELL LYMPHOMAS 125 
lection for the elderly (>70 years) and selected skin 
sites (lower legs) are briefly discussed in this article and 
extensively met in the article "Primary Cutaneous 
Large B-Cell Lymphomas" by Wechsler and Bagot on 
page 130 in this issue. 
CLINICAL FEATURES 
The majority of patients affected by CBCLs show a 
characteristic clinical presentation: localized, erythema- 
tous to cianotic, sometimes mammillated, rarely ulcer- 
ated plaques, nodules, or tumors of various size are 
very often surrounded by small papules and slightly 
infiltrated, sometimes figurate plaques (Figs 1 and 2), 
which are present for months to years before the 
appearance of larger lesions. The presence of the 
aforementioned "satellite" lesions surrounding the 
"main" lesion(s) can be an important clue in the early 
diagnosis of CBCI.s and their clinical differentiation 
from B-PLs. Conversely, the differential diagnosis be- 
twee, n CBCLs and B-PLs can be very difficult clinically 
when only isolated nodules or plaques, especially small 
ones (this presentation, although infrequent, is not 
exceptional), are present. Skin lesions usually have a 
regional distribution (88.7% in our series of 186 
patients), preferentially onthe trunk (51.2%), head and 
neck (23.3%) and, to a lesser extent, on the limbs 
(14.2%). Only 11.3% of patients had lesions located in 
noncontiguous anatomic sites, and the presentation 
with widespread, isseminated lesions is exceedingly 
rare in CBCLs. We did not observe any particular 
gender predilection in our study (97 males, 89 fe- 
males). The median age was 59 years (range 22-88). 
HISTOLOGIC, IMMUNOPHENOTYPIC, AND 
MOLECULAR FEATURES 
Presently it is clear that a "low grade" histologic 
picture is an incorrect and unreliable criterion to 
differentiate between CBCLs and B-PLs. The only 
reliable tool is the demonstration f B-cell monoclonal- 
ity by immunohistochemistry (Fig3) and/or molecular 
analysis by Southern blotting or polymerase chain 
reaction. 26-31 
It is indeed difficult to categorize CBCI_s according 
to the updated Kiel classification 3z or the Revised 
European-American Lymphoma (REAL) classifica- 
tion. 33 However, the approaches toa specific lassifica- 
tion are slightly different at present. The classification 
for CBCI.s recently proposed by the Cutaneous Lym- 
phoma Study Group of the EORTC, 22 mainly based on 
the experience of the DCLWG, lr distinguishes clinico- 
pathologic entities with indolent course (FCCL and 
IOMZL) from another with an intermediate course 
(so-called primary cutaneous large B-cell lymphoma of 
the leg)33; in addition, rare and undefined types are 
listed in the EORTC classification. 
Primary cutaneous FCCL and IOMZL, which affect 
more than 90% of all patients with a definite diagnosis 
of CBCL, share a good response to radiotherapy with a 
generally excellent prognosis and behave much better 
than morphologically similar lymphomas in the lymph 
nodes. Primary cutaneous FCCL 12.18 is characterized 
by regional esions mainly located on the trunk and 
scalp. Histologically, it is composed of cells reminiscent 
of the morphologies of FCCL, usually a mixture of 
small and large cleaved cells (putative centrocytes) and 
large cells with prominent nuclei and nucleoli (putative 
centroblasts and immunoblasts). It has a chronic ourse, 
is highly sensitive to radiotherapy, and has a good 
prognosis. Primary cutaneous IC 19 i5 clinically charac- 
terized by one or several, often deeply seated, nodules 
or tumors, is almost without exception located on arms 
or legs, and has an excellent prognosis. Histologically, 
lymphoplasmacytoid/plasma cellsare located at  the 
periphery of the nodular infiltrates, different from the 
dispersed istribution of the same cells in secondary 
cutaneous IC and nodal IC 32 (this is the main reason 
why other groups have suggested to define this entity 
as MZL). 2~ The identification of primary cutaneous 
large B-cell lymphoma of the legs, a rare subtype of 
CBCI_.s, is also mainly based on the DCLWG experi- 
ence. 25 
Some investigators have hypothesized that most 
CBCLs are indeed marginal cell (parafollicular/mono- 
cytoid) lymphomas, and that this is the reason for their 
good prognosis as opposed to the rare, "true" primary 
cutaneous FCCI..s. 34 Nevertheless, the striking ten- 
dency to remain localized and the very rare occurrence 
of bone marrow involvement differentiate CBCLs, simi- 
lar to MALT lymphomas, from marginal cell (monocyt- 
oid/parafollicular) lymphomas and justify their designa- 
tion as distinct entities. 
An Alternative View: The SALT Hypothesis 
Since 1988 at the International Symposium on 
Cutaneous Lymphoma held in Copenhagen, 3~and 
later, based on a larger study of patients, 15 we stressed 
the close similarities between CBCLs, morphologically 
classifiable either as so-called primary cutaneous FCCL 
or as IC/MZL, and B-cell lymphomas of MALT. 23.36 The 
majority of CBCLs show: (1) nonaggressive clinical 
behavior (localized isease, good response to orthovoh 
radiotherapy; low tendency to extracutaneous spread, 
and excellent prognosis); (2) subtle histologic differ- 
ences, both in terms of cellular morphology and 
architectural organization of the different cell types, 
from "true" FCCI_s and IC of the lymph nodes, so that 
their classification either as FCCLs or 1C is a strained. 
categorization; (3) tumor ceils with unimodal morpho-' 
metric features intermediate between those of centro- 
cytes and centroblasts ofnodal FCCLs (tumor cells are 
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not "true" centrocytes orcentroblasts)37; (4) character- 
istic polymorphism of the neoplastic ellular infiltrate, 
with cells sho~ving a fluent transition of shapes and 
sizes and resembling small centrocytes (centrocyte-like 
cells), 23 large anaplastic entrocytes, centroblasts of 
different subtypes, plasma and/or plasmacytoid cells, 
and immunoblasts (Fig 4). The relative proportion of 
each of these cell types and the extent of the reactive 
T-cell and B-cell infiltrate (often represented by reactive 
lymphoid follicles) are highly variable according to the 
size, age, and growth rate of lesions and do not have 
any significant correlation with the overall evolution of 
the disease. 15 A prevalence of centrocyte-like B cells, 
plasma/lymphoplasmacytoid cells, and an abundant, 
often overwhelming, infiltrate of small lymphocytes 
(mostly T cells) are characteristic features of early 
lesions, while a clear-cut prevalence of large blast-like 
cells and a scarce reactive infiltrate are the rule in late 
lesions. It is typical to find different histologic features 
(low grade and high grade) in different lesions in the 
same patient (Fig 5) and even in different areas of the 
same lesion (discordant/composite picture); (5) multi- 
phasic histologic features, ~vith the various cell types 
often grouped together ather than intermingled; (6) 
lymphoepithelial lesions (an occasional finding in 
CBCLs, different from MALT lymphomas); (7) very 
frequent CD5-,  CD10- phenotype of neoplastic B 
cells; (8) nerve growth factor receptor+, CD14-, 
CD21 __. phenotype of associated dendritic ells38; (9) 
lack of either t(ll;14)/t(14;18) translocation or bcl-l/ 
bcl-2 gene and c-myc oncogene rearrangements. 39,4~ 
Bcl-2 protein expression, usually absent in B-PLs, 39 is 
significantly more frequent in secondary than in pri- 
mary CBCL. 39,40 In addition, the relationship between 
bcl-2 expression and bcl-2 gene rearrangement is 
definitely closer in secondary than in primary CBCL. 39,40 
The aforementioned histologic and, more impor- 
tantly, phenotypic and genotypic features led us to 
hypothesize a possible common histogenesis for 
CBCI..s, in analogy with that proposed for MALT 
lymphomas 23,36 and so-called parafollicular/monocyt- 
old lymphomas. 41 The previously described histologic, 
immunophenotypic, and genotypic features argue 
against a"true" FCCL nature of tumor cells, and may be 
reasonably interpreted as indicative of an origin from a 
cell type capable of differentiation i to the various cell 
morphologies (centrocyte-like, centroblast-like, immu- 
noblast-like) observed in CBCLs as well as MALT 
lymphomas and parafollicular/monocytoid lympho- 
mas. 42 
TREATMENT AND PROGNOSIS 
Skin lesions are highly responsive to local radio- 
therapy (RT). I~,43-45 Indeed, most leading investigators 
currently agree that RT should be considered the 
elective treatment for most CBCLs. Concerning the 
most suitable techniques and the recommended doses, 
local orthovolt RT (LoRT) guarantees very good re- 
sults, 43~44 although electron beam and photon beam can 
also be used successfully. 45 We have been using LoRT 
(half-deep x-rays, contact x-rays, soft x-rays) for the 
last 2 decades, with excellent results, according to the 
following protocol: potency range 50 to 120 kV, single 
dose per field 2.5 to 5 Gy, total dose of 15 to 25 Gy 
delivered in 2 to 3 weeks in 4 to 8 fractions, irradiation 
fields (up to 20 cm in diameter) almost invariably 
including l to 2 cm of healthy skin around the lesions. 
In particular, the slightly infiltrated erythematous 
patches and plaques urrounding the larger nodules or 
tumors have to be included in the irradiation field. 
LoRT produced a complete remission in 98.2% of 115 
patients treated at presentation, with residual slight 
erythema and pigmentation. Small, isolated lesions can 
be surgically excised, with or without additional RT. 
Only rare patients with disseminated lesions, multiple 
relapses after RT, and, of course, those experiencing 
extracutaneous spread of disease should be treated at 
presentation with muhiagent chemotherapy (cyclophos- 
phamide, vincristine, prednisone [COP-] and cyclo- 
phosphamide, adriblastine, vincristine, prednisone 
[CHOP]-like regimens). 1~,43,4s 
The relapse rate is 26.3% in our study, with a 
disease-free interval ranging from 3 to 134 months 
(median 42). Most relapses are limited to the skin, very 
often outside the previously irradiated area and can be 
successfully retreated with LoRT. Extracutaneous spread 
is quite rare (8.9% in our series), ~vith an excellent 
actuarial survival rate (98.3% and 95.6% at 5 years and 
10 years, respectively). No significant differences were 
found in our study between disease-free period and/or 
relapse rate on one hand, and radiation dose, anatomic 
site, gender, age, histoarchitectural pattem (Fig 6), 
and/or cellular morphology of the infiltrating cells on 
the other hand. In particular, the small group of 
patients in our study with large B-cell lymphoma "de 
novo" (18 patients) did not show any significant 
difference in overall survival (88.9% at 5 years) as 
compared to the strikingly larger group of CBCLs 
having the characteristic clinicopathologic features of 
SALT-related B-cell lymphoma, notwithstanding the 
rapid growth of skin lesions, high proliferation rate, 
strong bcl-2 protein expression by neoplastic ells at 
presentation, predilection for the elderly (>70 years), 
and selected skin sites (lower limbs). 
CONCLUSION 
CBCks represent a distinct group of lymphoprolifer- 
ative diseases; they have to he clearly separated from 
non-Hodgkin's B-cell lymphomas with secondary cuta- 
neous involvement and from cutaneous B-Pks. The 
majority of CBCLs are characterized bya h6mogeneous 
clinical presentation and behavior, with good response 
to LoRT, a low tendency to extracutaneous spread, and 
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Fig I. Erythematous nodule surrounded bysmall 
papulo-nodular lesions on the back of a male 
patient. 
Fig 3. This figure emphasizes the crucial role of 
the demonstration of monoclonality by immunohis- 
tochemistry in the proper identification of CBCLs, 
and their distinction from B-PLs and inflammatory 
dermatoses. 
Fig 2. Large mammillated nodule surrounded 
by slightly infiltrated plaques and papulo-nodular 
lesions on the right mammary region of a male 
patient. 
Fig 4. Range of appearances of neoplastic cells 
in CBCLs. 
Fig 5. Typical clinical picture of CBCLs (top 
left). Biopsies performed in 2 different lesions of 
this patient evidenced different morphologies, indi- 
cating the continuum existing between the so- 
called cutaneous ICIMZL (A; top right hematoxylin 
and eosin, bottom right anti-X) and (B) the so- 
called cutaneous FCCL and making questionable 
the Identification of histologic subgroups in CB- 
CLs. 
Fig 6. Histoarchitectural patterns of the infil- 
trate in CBCl.s. The nodular pattern (top left and 
right) is typical of young lesions (aged <~ 3months). 
The diffuse pattern (bottom right) is characteristic. 
of old lesions (aged >12 months). The mixed 
pattern (bottom left), although not characteristic 
of any specific age of lesion, is the most frequently 
observed. 
'128 PIMPINELLI AND SANTUCCI 
excellent prognosis. 15'46'47 The close similarities be- 
tween CBCLs and MALT lymphomas, and the evidence 
for an acquired B-cell arm of SALT prompted us to 
designate these CBCLs as SALT-related B-cell lympho- 
ma5.24,46-48 
A matter of further debate is whether the rare, 
so-called large B-cell lymphoma of the leg, the third 
subgroup of primary CBCL identified in the EORTC 
classification, 2' should indeed be regarded as a distinct 
clinicopathologic entity. 49 In this regard, an EORTC 
muhicenter study, chaired by the French Cutaneous 
Lymphoma Study Group, is ongoing. The preliminary 
results of the study suggest hat old age (>70 years) 
and de novo "round" large cell histology (noncleaved 
cells, ie, centroblast-) (and immunoblast-like c lls) are 
indeed significantly related to a worse prognosis in a 
multivariate analysis, while the lower limb location is 
not. 5o 
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